BeiGene's Brukinsa Fails In Head-To-Head But Hope Remains For Rare Indication
Signs Of Benefit Vs Imbruvica
Days after bagging a US approval for its first global new drug, BeiGene was dealt a blow as its BTK inhibitor Brukinsa showed no significant superiority over class leader Imbruvica in Waldenström's macroglobulinemia, although the Chinese company remains hopeful for a possible approval.
You may also be interested in...
Beijing-based BeiGene is set to score two big wins in a row as it pursues innovation. After securing US approval for its BTK inhibitor zanubrutinib for mantle cell lymphoma, its PD-1 inhibitor has sailed through a technical review in China.
Keeping Track Of User Fee Decisions And Filings: Adakveo, Brukinsa And Fetroja Mark Massive Week Of Novel Approvals
The latest news on US FDA user fee decisions and submissions to the agency.
From BeiGene to Innovent to Wuxi Biologics, executives at Chinese pharma firms are now discussing collaborations to go beyond China to become biopharma operations with a truly global presence.